[Study of rifampicin in the treatment of tuberculosis and nonspecific inflammatory lung diseases].
Benemecin, a Polish rifampicin was tested in vitro and clinically for the treatment of 2 groups of patients, i.e. 28 patients with chronic destructive tuberculosis of the lungs and 30 patients with non-specific pneumonia. High tuberculostatic activity of the drug in vitro was found. The clinical trials showed high efficiency of benemecin in the treatment of chronic destructive tuberculosis of the lungs and pneumonia of non-specific etiology. The drug was mainly well tolerated by the patients.
D002908:Chronic Disease; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007558:Italy; D008171:Lung Diseases / Q000188:drug therapy*; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011014:Pneumonia / Q000188:drug therapy; D011044:Poland; D011182:Postoperative Care; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D015022:Yugoslavia
D004977:Ethambutol; D012293:Rifampin
Izuchenie rifampitsina pri lechenii bol'nykh tuberkulezom i s nespetsificheskimi vospalitel'nymi zabolevaniiami legkikh